It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Despite expanded antiretroviral therapy (ART) in South Africa, HIV-1 transmission persists. Integrase strand transfer inhibitors (INSTI) and long-acting injectables offer potential for superior viral suppression, but pre-existing drug resistance could threaten their effectiveness. In a community-based study in rural KwaZulu-Natal, prior to widespread INSTI usage, we enroled 18,025 individuals to characterise HIV-1 drug resistance and transmission networks to inform public health strategies. HIV testing and reflex viral load quantification were performed, with deep sequencing (20% variant threshold) used to detect resistance mutations. Phylogenetic and geospatial analyses characterised transmission clusters. One-third of participants were HIV-positive, with 21.7% having detectable viral loads; 62.1% of those with detectable viral loads were ART-naïve. Resistance to older reverse transcriptase (RT)-targeting drugs was found, but INSTI resistance remained low (<1%). Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, particularly to rilpivirine (RPV) even in ART-naïve individuals, was concerning. Twenty percent of sequenced individuals belonged to transmission clusters, with geographic analysis highlighting higher clustering in peripheral and rural areas. Our findings suggest promise for INSTI-based strategies in this setting but underscore the need for RPV resistance screening before implementing long-acting cabotegravir (CAB) + RPV. The significant clustering emphasises the importance of geographically targeted interventions to effectively curb HIV-1 transmission.
There is limited data on drug resistance in South African communities strongly affected by HIV. In this study, the authors observed low levels of resistance to newer drugs but widespread resistance to older HIV medications in a South African community. Resistance to rilpivirine was detected even in untreated individuals.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 University of Cambridge, Department of Medicine, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); University of Oxford, Pandemic Science Institute, Big Data Institute, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
2 University of Cambridge, Department of Medicine, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934)
3 University of Cincinnati, Digital Epidemiology Laboratory, Digital Futures, Cincinnati, USA (GRID:grid.24827.3b) (ISNI:0000 0001 2179 9593)
4 KwaZulu-Natal, Africa Health Research Institute, Durban, South Africa (GRID:grid.488675.0) (ISNI:0000 0004 8337 9561)
5 KwaZulu-Natal, Africa Health Research Institute, Durban, South Africa (GRID:grid.488675.0) (ISNI:0000 0004 8337 9561); University College London, London, UK (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201)
6 University College London, London, UK (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201)
7 University of Oxford, Pandemic Science Institute, Big Data Institute, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
8 University of Stellenbosch, Cape Town, South Africa (GRID:grid.11956.3a) (ISNI:0000 0001 2214 904X)
9 KwaZulu-Natal, Africa Health Research Institute, Durban, South Africa (GRID:grid.488675.0) (ISNI:0000 0004 8337 9561); Massachusetts General Hospital, Division of Infectious Diseases, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); University of KwaZulu-Natal, Durban, South Africa (GRID:grid.16463.36) (ISNI:0000 0001 0723 4123); Harvard University, Cambridge, England (GRID:grid.38142.3c) (ISNI:0000 0004 1936 754X)
10 University of Cambridge, Department of Medicine, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); KwaZulu-Natal, Africa Health Research Institute, Durban, South Africa (GRID:grid.488675.0) (ISNI:0000 0004 8337 9561)